Prodigy

ProdIgY Biotech is a private biopharmaceutical company developing avian IgY-based antibody therapeutics designed to modulate the microbiome without broadly disrupting commensal flora. The company is focused primarily on liver diseases mediated through the gut-liver axis, especially alcohol-associated hepatitis and related alcohol-associated liver disease, and is also exploring transplant-related microbiome applications. Its approach uses polyclonal IgY antibodies to selectively neutralize pathogenic microbes, toxins, and inflammatory drivers such as Enterococcus-associated factors while preserving beneficial bacteria. ProdIgY has highlighted preclinical programs built on targeted, gut-localized biologic intervention and has announced a sponsored research collaboration with Memorial Sloan Kettering Cancer Center in allogeneic hematopoietic stem cell transplantation. Overall, the company appears to be an early-stage platform biotech centered on microbiome-directed antibody therapeutics.